WUXI APPTEC - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

does not make any representation about the accuracy or completeness of this announcement and expressly disclaims any liability arising out of or in connection with all or any part of this announcement. We are not responsible for any losses caused by reliance on such content. WUXI APPTEC CO., LTD.* Wuxi WuXi AppTec New Drug Development Co., Ltd. (a joint stock limited company incorporated in the People's Republic of China) (Stock code: 2359) Overseas Regulatory Announcements This overseas regulatory announcement is made by the Company in accordance with Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited Section 13.10B is made. The full Chinese text of the following information published by the Company on the Shanghai Stock Exchange website is hereby provided for reference only. By order of the board of directors Wuxi WuXi AppTec New Drug Development Co., Ltd. Chairman Dr. Li Ge Hong Kong, March 23, 2026 As of the date of this announcement, the Company's Board of Directors includes executive directors Dr. Li Ge, Dr. Chen Minzhang, Dr. Yang Qing and Mr. Zhang Zhaohui; Non-executive directors Mr. Tong Xiaoyi and Dr. Wu Yibing; and independent non-executive directors Ms. Lu Shaohua, Dr. Yu Wei, Dr. Zhang Xin, Ms. Zhan Zhiling and Mr. Leng Xuesong. *For identification only Wuxi WuXi AppTec New Drug Development Co., Ltd. Internal Control Audit Report December 31, 2025 Internal Control Audit Report Deshibao (review) No. (26) P03784 (Page 1 of 2) All shareholders of Wuxi WuXi AppTec New Drug Development Co., Ltd.: In accordance with the relevant requirements of the "Audit Guidelines for Enterprise Internal Control" and the Chinese Certified Public Accountants Practice Standards, we audited all Internal controls over financial reporting of XiwuXing AppTec New Drug Development Co., Ltd. (hereinafter referred to as "your company") as of December 31, 2025 effectiveness of the system. 1. Enterprise’s Responsibility for Internal Control In accordance with the "Basic Standards for Enterprise Internal Control", "Guidelines for the Application of Enterprise Internal Control", "Enterprise Internal Control Evaluation Guidelines" According to the provisions of the "Introduction", it is the responsibility of your company's board of directors to establish, improve and effectively implement internal controls and evaluate their effectiveness. 2. Responsibilities of Certified Public Accountants Our responsibility is to express an audit opinion on the effectiveness of internal control over financial reporting based on our audit work. and disclose significant deficiencies in internal control over non-financial reporting that are noted. 3. Inherent limitations of internal control Internal controls have inherent limitations and may fail to prevent and detect misstatements. In addition, due to changes in circumstances may cause internal controls to become inappropriate or to reduce the degree of compliance with control policies and procedures. According to the results of the internal control audit, It is risky to speculate on the effectiveness of internal control in the future. Internal Control Audit Report - Continued Deshibao (review) No. (26) P03784 (Page 2 of 2) 4. Audit opinions on internal control over financial reporting We believe that on December 31, 2025, your company was in compliance with the "Basic Standards for Enterprise Internal Control" and relevant regulations. There are significant aspects in which effective internal control over financial reporting is maintained. Deloitte Touche Tohmatsu Certified Public Accountants LLP (Special General Partnership) Chinese Certified Public Accountant: Mu Lanying China·Shanghai Chinese Certified Public Accountant: Lin Qiumei March 23, 2026